1. Home
  2. HCAI vs CVKD Comparison

HCAI vs CVKD Comparison

Compare HCAI & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HCAI

Huachen AI Parking Management Technology Holding Co. Ltd. Ordinary Shares

HOLD

Current Price

$4.32

Market Cap

7.7M

ML Signal

HOLD

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$2.01

Market Cap

6.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HCAI
CVKD
Founded
2004
2022
Country
China
United States
Employees
N/A
5
Industry
Miscellaneous manufacturing industries
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7M
6.2M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
HCAI
CVKD
Price
$4.32
$2.01
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$13.00
AVG Volume (30 Days)
30.5K
61.9K
Earning Date
05-23-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
23.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$63.07
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.13
$1.86
52 Week High
$25.99
$14.64

Technical Indicators

Market Signals
Indicator
HCAI
CVKD
Relative Strength Index (RSI) 28.17 31.26
Support Level $0.24 $1.86
Resistance Level $9.73 $3.89
Average True Range (ATR) 0.62 0.20
MACD -0.22 0.04
Stochastic Oscillator 2.66 21.71

Price Performance

Historical Comparison
HCAI
CVKD

About HCAI Huachen AI Parking Management Technology Holding Co. Ltd. Ordinary Shares

Huachen AI Parking Management Technology Holding Co Ltd is a comprehensive smart parking solutions and equipment structural parts provider. The company manufactures and offer various cubic parking garage products by employing various working principles, such as lifting and shifting, convenient lifting, vertical circulation, vertical lifting, plane moving, alley stacking, multi-layer cycle, horizontal cycle, and car lift.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Share on Social Networks: